Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lapatinib Ditosylate

FDA-approved product (tablet, oral), marketed as Lapatinib Ditosylate, Tykerb.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lapatinib Ditosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • HER2 Positive Breast Carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Human epidermal growth factor receptor 2 (her2) tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lapatinib Ditosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lapatinib Ditosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

    NCT01454804 · start 2011-10

    Registered record
    Registry ID
    NCT01454804
    Conditions
    Advanced Cancers
    Interventions
    Pazopanib; Lapatinib; Trastuzumab (Herceptin®); Pazopanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-10
    Completion
    2015-03
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancers
    InterventionPazopanib; Lapatinib; Trastuzumab (Herceptin®); Pazopanib
    PhasePhase 1
    Registry statusCompleted

  • Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib

    NCT01847599 · start 2011-09-06

    Registered record
    Registry ID
    NCT01847599
    Conditions
    Metastatic Breast Cancer; Colorectal Cancer
    Interventions
    Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2011-09-06
    Completion
    2017-07-02
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer; Colorectal Cancer
    InterventionEducational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib
    PhaseNot applicable
    Registry statusTerminated

  • A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

    NCT01419197 · start 2011-09

    Registered record
    Registry ID
    NCT01419197
    Conditions
    Breast Cancer
    Interventions
    Trastuzumab emtansine; Treatment of physician's choice
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2015-08
    Enrolment
    602

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionTrastuzumab emtansine; Treatment of physician's choice
    PhasePhase 3
    Registry statusCompleted

  • Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease

    NCT01427322 · start 2011-09

    Registered record
    Registry ID
    NCT01427322
    Conditions
    Epithelial Cancer
    Interventions
    Lapatinib; Radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2011-09
    Completion
    2015-07
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpithelial Cancer
    InterventionLapatinib; Radiation therapy
    PhaseEarly phase 1
    Registry statusTerminated

  • Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

    NCT01426880 · start 2011-08

    Registered record
    Registry ID
    NCT01426880
    Conditions
    Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer
    Interventions
    Carboplatin; background treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2013-08
    Enrolment
    595

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer +4 more
    InterventionCarboplatin; background treatment
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

    NCT01273610 · start 2011-04-20

    Registered record
    Registry ID
    NCT01273610
    Conditions
    Breast Neoplasms; HER2/Neu Positive; Geriatric Health Services
    Interventions
    Lapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2011-04-20
    Completion
    2027-04-20
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; HER2/Neu Positive; Geriatric Health Services
    InterventionLapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study
    PhasePhase 2
    Registry statusActive not recruiting

  • The Myocet/Lapatinib Study. ICORG 10-03, V5

    NCT01495884 · start 2011-03

    Registered record
    Registry ID
    NCT01495884
    Conditions
    Her2 Positive Metastatic Breast Cancer
    Interventions
    non-pegylated liposomal doxorubicon (Myocet™); Lapatinib (Tyverb™)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2011-03
    Completion
    2014-10
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHer2 Positive Metastatic Breast Cancer
    Interventionnon-pegylated liposomal doxorubicon (Myocet™); Lapatinib (Tyverb™)
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

    NCT01306045 · start 2011-02-08

    Registered record
    Registry ID
    NCT01306045
    Conditions
    Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell Lung; Carcinoma, Thymic
    Interventions
    AZD6244; MK-2206; Lapatinib; Erlotinib; Sunitinib; Molecular Profiling
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-02-08
    Completion
    2024-07-17
    Enrolment
    647

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell Lung; Carcinoma, Thymic
    InterventionAZD6244; MK-2206; Lapatinib; Erlotinib +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy

    NCT01245660 · start 2011-01

    Registered record
    Registry ID
    NCT01245660
    Conditions
    Bladder Carcinoma; Infiltrative Bladder Carcinoma; Cystectomy
    Interventions
    LAPATINIB
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2011-01
    Completion
    2011-10
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Carcinoma; Infiltrative Bladder Carcinoma; Cystectomy
    InterventionLAPATINIB
    PhaseEarly phase 1
    Registry statusTerminated

  • Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

    NCT01245205 · start 2010-11

    Registered record
    Registry ID
    NCT01245205
    Conditions
    HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    Akt inhibitor MK2206; lapatinib ditosylate; pharmacological study; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-11
    Completion
    Not recorded
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer +3 more
    InterventionAkt inhibitor MK2206; lapatinib ditosylate; pharmacological study; laboratory biomarker analysis
    PhasePhase 1
    Registry statusCompleted

  • Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC

    NCT01138046 · start 2010-04

    Registered record
    Registry ID
    NCT01138046
    Conditions
    Neoplasms, Breast
    Interventions
    Lapatinib in combination with weekly paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04
    Completion
    2014-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms, Breast
    InterventionLapatinib in combination with weekly paclitaxel
    PhasePhase 2
    Registry statusCompleted

  • Regulatory TYKERB® Tablets PMS

    NCT00975988 · start 2010-01

    Registered record
    Registry ID
    NCT00975988
    Conditions
    Cancer
    Interventions
    TYKERB® tablets
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-01
    Completion
    2014-07
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionTYKERB® tablets
    PhaseNot recorded
    Registry statusCompleted

  • A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

    NCT00996762 · start 2009-11-12

    Registered record
    Registry ID
    NCT00996762
    Conditions
    Neoplasms, Breast
    Interventions
    lapatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-11-12
    Completion
    2012-09-18
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms, Breast
    Interventionlapatinib
    PhasePhase 1
    Registry statusCompleted

  • Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

    NCT00881621 · start 2009-08

    Registered record
    Registry ID
    NCT00881621
    Conditions
    Pancreas Cancer
    Interventions
    Lapatinib and Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-08
    Completion
    2013-06
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreas Cancer
    InterventionLapatinib and Capecitabine
    PhasePhase 2
    Registry statusTerminated

  • Drug Use Investigation for TYKERB Tablet (All Case Investigation)

    NCT01332396 · start 2009-06

    Registered record
    Registry ID
    NCT01332396
    Conditions
    Cancer
    Interventions
    Lapatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-06
    Completion
    2017-03-13
    Enrolment
    4,054

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionLapatinib
    PhaseNot recorded
    Registry statusCompleted